Section Arrow
ARTL.NASDAQ
- Artelo Biosciences Inc
(Financial Status)
Quotes are at least 15-min delayed:2025/07/21 06:59 EDT
Pre Market
Last
 14.94
-0.01 (-0.07%)
Bid
14.01
Ask
20.77
High 14.94 
Low 14.94 
Volume 18 
Regular Hours
Last
 14.95
-0.72 (-4.59%)
Day High 
16.1623 
Prev. Close
15.67 
1-M High
28.6 
Volume 
93.16K 
Bid
14.01
Ask
20.77
Day Low
14.72 
Open
15.38 
1-M Low
5.76 
Market Cap 
8.57M 
Currency USD 
P/E -- 
%Yield 7.86 
10-SMA 17.97 
20-SMA 12.84 
50-SMA 8.87 
52-W High 28.6 
52-W Low 4.9176 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-17.94/-1.68
Enterprise Value
8.64M
Balance Sheet
Book Value Per Share
1.19
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 1.98 -0.3 -13.16%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.01 -1.065 -7.57%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0473 -0.0004 -0.84%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.22 +0.38 +6.51%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.17 +0.25 +4.22%
Quotes are at least 15-min delayed:2025/07/21 06:59 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors& neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.